Jefferies Financial Group’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.1M Sell
28,000
-65,400
-70% -$2.53M 0.01% 746
2026
Q2
$3.4M Buy
+93,400
New +$2.95M 0.02% 506
2026
Q1
– Sell
-29,251
Closed -$1.09M – 1949
2025
Q4
$1.09M Sell
29,251
-173,704
-86% -$5.71M 0.01% 1030
2025
Q3
$5.59M Buy
202,955
+32,385
+19% +$1.12M 0.03% 342
2025
Q2
$5.39M Buy
170,570
+26,326
+18% +$847K 0.05% 280
2025
Q1
$4.79M Sell
144,244
-161,356
-53% -$5.78M 0.04% 303
2024
Q4
$10.5M Buy
305,600
+89,000
+41% +$3.06M 0.06% 217
2024
Q3
$8.66M Buy
216,600
+166,100
+329% +$5.83M 0.06% 201
2024
Q2
$1.52M Buy
50,500
+25,000
+98% +$752K 0.02% 617
2024
Q1
$856K Buy
25,500
+4,800
+23% +$154K 0.01% 872
2023
Q4
$669K Buy
+20,700
New +$578K ﹤0.01% 1106
2023
Q3
– Sell
-10,000
Closed -$352K – 1767
2023
Q2
$352K Buy
+10,000
New +$345K ﹤0.01% 1279

Other funds holding HRMY

Jefferies Financial Group's HRMY Position: Q3 2026 in Review

Jefferies Financial Group reduced its Harmony Biosciences (HRMY) stake by 70% in Q3 2026, selling an estimated $2.53M and leaving 28,000 shares worth $1.1M. The position accounts for 0.01% of the portfolio, ranked #746.

Jefferies Financial Group first reported a position in HRMY in Q2 2023 and has held it in 12 quarters since. The position peaked at $10.5M in Q4 2024. 358 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Jefferies Financial Group held 28,000 shares of Harmony Biosciences worth $1.1M as of Q3 2026.
  • Jefferies Financial Group sold 65,400 Harmony Biosciences shares in Q3 2026, an estimated $2.53M.
  • Harmony Biosciences made up 0.01% of Jefferies Financial Group's portfolio in Q3 2026, its #746 holding.
  • Jefferies Financial Group first reported a position in Harmony Biosciences in Q2 2023 and has held it in 12 quarters since.
  • Jefferies Financial Group's Harmony Biosciences position peaked at $10.5M in Q4 2024.
  • 358 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.